tiprankstipranks
Trending News
More News >

SAB Biotherapeutics initiated with a Buy at Brookline

Brookline initiated coverage of SAB Biotherapeutics with a Buy rating and $8 price target.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1